Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2001 Jan;45(1):349-52.
doi: 10.1128/AAC.45.1.349-352.2001.

Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative

Affiliations
Case Reports

Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative

S Bobin-Dubreux et al. Antimicrob Agents Chemother. 2001 Jan.

Abstract

A Staphylococcus aureus strain with low-level heteroresistance to vancomycin (designated MER) but susceptible to methicillin was isolated from an outpatient with conjunctivitis who did not receive any glycopeptide antibiotics. Incubation of the parent strain, MER, with increasing concentrations of vancomycin led to rapid selection of a stable progeny homogeneously resistant to vancomycin. Electron micrographs of strain MER showed enhanced cell wall thickness and abnormal septations typically seen with methicillin-resistant S. aureus having intermediate susceptibility to vancomycin.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Population analysis of parental hVISA strain MER, S. aureus ATCC 29213, and their derivatives. Bacteria grown overnight were serially diluted and plated on various concentrations of vancomycin-containing agar medium. MER-S6 was a MER-derived progeny selected at 6 μg of vancomycin per ml, MER-S12 was derived from MER-S6 selected at 12 μg of vancomycin per ml, and MER-S20 was derived from MER-S12 selected at 20 μg of vancomycin per ml. ATCC 29213-S3 was selected at 3 μg of vancomycin per ml, ATCC 29213-S4 was selected at 4 μg of vancomycin per ml, and ATCC 29213-S4′ was obtained by selecting ATCC 29213-S4 with 4 μg of vancomycin per ml. Horizontal arrows indicate the order in which the consecutive population analyses were performed.
FIG. 2
FIG. 2
Composite picture showing the morphology of S. aureus ATCC 29213 (A) susceptible to vancomycin and the morphological abnormalities of hVISA MER grown in the absence (B) or presence (C) of 2 μg of vancomycin per ml and of strain MER-S20 (D). All cultures were grown to an optical density at 600 nm of 0.6 in brain heart infusion broth prior to processing for transmission electron microscopic examination. Magnification, ×40,000 (original magnification, ×60,000).

References

    1. Boyle-Vavra S, Berke S K, Lee J C, Daum R S. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother. 2000;44:272–277. - PMC - PubMed
    1. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin—United States 1997. Morb Mortal Wkly Rep. 1997;46:765–766. - PubMed
    1. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum R S, Labischinski H, Hiramatsu K. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother. 1998;42:199–209. - PubMed
    1. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997;350:1670–1673. - PubMed
    1. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover F C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997;40:135–136. - PubMed

Publication types

MeSH terms